National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Department of Immunization Program Planning, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
J Infect Dis. 2024 Jan 12;229(1):117-121. doi: 10.1093/infdis/jiad338.
Using a prospective, observational cohort study during the post-"dynamic COVID-zero" wave in China, we estimated short-term relative effectiveness against Omicron BA.5 infection of inhaled aerosolized adenovirus type 5-vectored ancestral strain coronavirus disease 2019 (COVID-19) vaccine as a second booster dose approximately 1 year after homologous boosted primary series of inactivated COVID-19 vaccine compared with no second booster. Participants reported nucleic acid or antigen test results weekly until they tested positive or completed predesignated follow-up. After excluding participants infected <14 days after study entry, relative effectiveness among the 6576 participants was 61% in 18- to 59-year-olds and 38% in ≥60-year-olds and was sustained for 12 weeks.
采用在中国“动态清零”后阶段的前瞻性、观察性队列研究，我们估计，与无第二剂加强针相比，在同源加强免疫接种灭活 COVID-19 疫苗后约 1 年，吸入雾化腺病毒 5 型载体新冠病毒病 2019（COVID-19）疫苗作为第二剂加强针，对奥密克戎 BA.5 感染的短期相对有效性。参与者每周报告核酸或抗原检测结果，直到他们检测呈阳性或完成预定的随访。在排除研究入组后 <14 天感染的参与者后，在 18 至 59 岁的 6576 名参与者中，相对有效性为 61%，在 ≥60 岁的参与者中为 38%，并持续 12 周。
